Evidence map›Paper›PMID 29119710›Full record

ArticleStem cells translational medicine2018

Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes.

Maritza E Mayorga, Matthew Kiedrowski, Patricia McCallinhart, Farhad Forudi, Jeremiah Ockunzzi, Kristal Weber, William Chilian, Marc S Penn, Feng Dong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. The Potential of Mesenchymal Stem Cell-Derived Exosomes in Cardiac Repair.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Chemokines in Myocardial Infarction.Journal of cardiovascular translational research · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Maritza E MayorgaDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Matthew KiedrowskiDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Patricia McCallinhartDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Farhad ForudiDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Jeremiah OckunzziDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Kristal WeberDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
William ChilianDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Marc S PennDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.
Feng DongDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, Rootstown, Ohio, USA.ORCID 0000-0003-3557-7099
Northeast Ohio Medical University · USSumma Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is a risk factor for worse outcomes following acute myocardial infarction (AMI). In this study, we tested the hypothesis that SDF-1:CXCR4 expression is compromised in post-AMI in diabetes, and that reversal of this defect can reverse the adverse effects of diabetes. Mesenchymal stem cells (MSC) isolated from green fluorescent protein (GFP) transgenic mice (control MSC) were induced to overexpress stromal cell-derived factor-1 (SDF-1). SDF-1 expression in control MSC and SDF-1-overexpressing MSC (SDF-1:MSC) were quantified using enzyme-linked immunosorbent assay (ELISA). AMI was induced on db/db and control mice. Mice were randomly selected to receive infusion of control MSC, SDF-1:MSC, or saline into the border zone after AMI. Serial echocardiography was used to assess cardiac function. SDF-1 and CXCR4 mRNA expression in the infarct zone of db/db mice and control mice were quantified. Compared to control mice, SDF-1 levels were decreased 82%, 91%, and 45% at baseline, 1 day and 3 days post-AMI in db/db mice, respectively. CXCR4 levels are increased 233% at baseline and 54% 5 days post-AMI in db/db mice. Administration of control MSC led to a significant improvement in ejection fraction (EF) in control mice but not in db/db mice 21 days after AMI. In contrast, administration of SDF-1:MSC produced a significant improvement in EF in both control mice and db/db mice 21 days after AMI. The SDF-1:CXCR4 axis is compromised in diabetes, which appears to augment the deleterious consequences of AMI. Over-express of SDF-1 expression in diabetes rescues cardiac function post AMI. Our results suggest that modulation of SDF-1 may improve post-AMI cardiac repair in diabetes. Stem Cells Translational Medicine 2018;7:115-124.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsApoptosisChemokine CXCL12Diabetes MellitusMaleMesenchymal Stem CellsMiceMice, Inbred C57BLMice, Inbred NODMyocardial InfarctionReceptors, CXCR4Stroke VolumeChemokine CXCL12Cxcl12 protein, mouseCXCR4 protein, mouseReceptors, CXCR4CardiacCell therapyDiabetesStem cellsStromal derived factor-1

Identifiers

PMID29119710
PMCPMC5746149
OpenAlexW2767387205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.